Alignment with the FDA enables a Q4 NDA submission for AXPAXLI in wet AMD, leveraging strong single-trial data and the 505(b)(2) pathway. The product shows superior durability, robust safety, and is expected to see broad adoption, with commercial and financial readiness in place.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.